Company Overview and News
KUALA LUMPUR (Aug 10): Former Tradewinds Plantation Bhd chief executive officer (CEO) Chan Seng Fatt will join the board of directors of Star Media Group Bhd effective tomorrow (Aug 11).
6084 9318 0806 VPGLF BSMAF 1818
KUALA LUMPUR (Aug 3): Shares of water pipe manufacturers rose today as the Selangor government announced it would offer RM2.25 billion to take over Syarikat Bekalan Air Selangor Sdn Bhd (Splash), in a move towards solving the impasse over the state's water assets.
5843 9318 5072 7014 5056
KUALA LUMPUR (June 22): Based on corporate announcements and news flow today, companies that may be in focus on Monday (June 25) may include the following: Willowglen MSC Bhd, Icon Offshore Bhd, Green Packet Bhd, Comfort Gloves Bhd, Kimlun Corp Bhd, Malaysia Airports Holdings Bhd (MAHB), Fitters Diversified Bhd and SCGM Bhd.
9318 2127 0008 MYPRY 0082 5014 5255
KUALA LUMPUR: JF Apex Research expects Fitters Diversified Bhd , Datasonic Group Bhd , Cypark Resources Bhd , Benalec Holdings Bhd and CCK Consolidated Holdings Bhd to be among the stocks to watch on Thursday.
5190 5216 9318 5184 7035
Mohd Farid Mohd Nor, the CEO of Molecor (SEA) Sdn Bhd (left) shaking hands with Devan Iyavoo, the CEO of Felda Water. From left are Datuk Shahlan Ismail, Strategic Advisor, Prime Minister's Department; Datuk Seri Dr Zaini Ujang, Ketua Setiausaha KeTTHa; Senator Datuk Seri SK Devamany, Deputy Minister, KeTTHa; Datuk Richard Wong, managing director of Fitters Diversified Bhd and Datuk Fu Ah Kiow, chaiman, Fitters Diversified.
4h - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
2018-09-18 - Asif
Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...